Tricida
company
About
Tricida operates in the healthcare industry focusing on pharmaceutical business.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $125M
- Industries
- Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
6
$377.50M
Tricida has raised a total of
$377.50M
in funding over 2 rounds. Their latest funding was raised on
Oct 19, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 19, 2022 | Post-IPO Debt | $125M | 1 |
Hercules Capital
|
— | Detail |
| Mar 2, 2018 | Debt Financing | $100M | 1 |
Hercules Capital
|
— | Detail |
| Nov 8, 2017 | Series D | $57.50M | 1 | — | — | Detail |
| Jul 25, 2016 | Series C | $55M | 1 | — | — | Detail |
| Mar 4, 2015 | Series B | $30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
2
Tricida is funded by 2 investors.
Hercules Capital
and Limulus Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
